Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights * Revenue of $2.3 million, a 29.0% increase over Q3 2025 * Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 * Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End * On April 18, 2026, President Donald Trump signed an executive order directing U.S. federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD, and committing US$50 million in federal support for state-level programs. The Company views this as a meaningful regulatory development for its clinical research operations and practitioner training programs, both of which are actively engaged in psychedelic research delivery and practitioner readiness. The ultimate impact, however, will depend on further agency implementation by the FDA and DEA. All financial results are reported in Canadian dollars unless otherwise stated.